Antitumor activity observed in a phase I drug–drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e13042-e13042 ◽  
Author(s):  
T. K. Choueiri ◽  
S. K. Pal ◽  
M. E. Cabanillas ◽  
D. A. Ramies ◽  
L. Tseng ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Thyroid Cancer ◽  
Drug Interaction ◽  
Antitumor Activity ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Differentiated Thyroid Cancer ◽  
Interaction Study ◽  
Drug Interaction Study

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

2008 ◽  
Vol 26 (12) ◽  
pp. 2034-2039 ◽  
Author(s):  
John A. Thompson ◽  
Brendan D. Curti ◽  
Bruce G. Redman ◽  
Shailender Bhatia ◽  
Jeffrey S. Weber ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Antitumor Activity ◽  
Phase I ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Study ◽  
Maximum Tolerated Dose ◽  
Systemic Treatments ◽  
Interleukin 21 ◽  
Dose Dependent

Purpose A phase I study of patients with metastatic malignant melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of recombinant human interleukin-21 (rIL-21). Patients and Methods Patients who had one or fewer prior systemic treatments for metastatic MM or RCC were treated with rIL-21 administered for two 5-day cycles on days 1 through 5 and 15 through 19 of a treatment course; rIL-21 was administered by rapid intravenous infusion in an outpatient setting. Cohorts of patients received doses ranging from 3 to 100 μg/kg/dose, and an expanded cohort was treated at the MTD. Patients with stable disease (SD) or better could receive additional treatment cycles. Results Forty-three patients were treated (24 MM; 19 RCC), including 28 in the expanded cohort. Dose-limiting toxicities consisted primarily of transient grade 3 laboratory abnormalities. The MTD was estimated to be 30 μg/kg. The most common adverse events included flu-like symptoms, pruritus, and rash. Twelve patients received up to five additional two-cycle courses of treatment without cumulative toxicity, except for one patient with reversible grade 4 hepatotoxicity. Serum concentrations of rIL-21 increased in a dose-proportional manner. Dose-dependent increases in soluble CD25 reflected lymphocyte activation. Antitumor activity was observed in both MM (one complete response and 11 SD) and RCC (four partial responses, 13 SD). Conclusion Outpatient therapy with rIL-21 at 30 μg/kg was well tolerated, had dose-dependent pharmacokinetics and pharmacodynamics, and was associated with antitumor activity in patients with MM and RCC.

scholarly journals A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma

2014 ◽  
Vol 37 (3) ◽  
pp. 180-186 ◽  
Author(s):  
Paul Monk ◽  
Elaine Lam ◽  
Amir Mortazavi ◽  
Kari Kendra ◽  
Gregory B. Lesinski ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase I Study ◽  
Interleukin 2 ◽  
High Dose

Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

2003 ◽  
Vol 52 (11) ◽  
pp. 699-707 ◽  
Author(s):  
Françoise Bouet-Toussaint ◽  
Jean-Jacques Patard ◽  
Alban Gervais ◽  
Noëlle Genetet ◽  
Cécile Thomas de la Pintière ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Antitumor Activity ◽  
Cell Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Ex Vivo ◽  
Effector Cells ◽  
Cytotoxic Effector
Sign in / Sign up

Export Citation Format

Share Document